Skip to main content

Pulmonary Arterial Hypertension (PAH) Market Projected to Gain Significant Value by 2020


Global Pulmonary Arterial Hypertension Market: Snapshot

Pulmonary arterial hypertension (PAH) is an uncommon type of progressive illness linked with high blood pressure. Nevertheless, the last few years, the increasing prevalence of PAH disorder due to rising risk factors such as HIV, sedentary lifestyle, tobacco and alcohol consumption, smoking, and other idiopathic conditions. As per the study conducted by World Health Organization and Centre for Disease Control and Prevention suggests that the prevalence of PAH is estimated to about 15 to 50 cases per million heads, and there is no everlasting cure for this disorder present in the market. Therefore, there is a high growth opportunities for the market to grow in the near future.

Request Sample Of Report –   https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

Various treatment are available in the market that helps in controlling and slowing down the growth of the diseases and improves the quality of life. In addition, the approval of few effective drugs and the occurrence of favorable pipeline are some of primary factors that drive the market growth. Favorable policies by government has contributed in boosting the demand in the global pulmonary arterial hypertension market.

Buy _ Research Report Now –  https://www.transparencymarketresearch.com/checkout.php?rep_id=1181&ltype=S

According to Transparency Market Research, the global pulmonary arterial hypertension market is projected to rise at a promising CAGR of 17.90% over the forecast tenure between 2014 and 2020. In terms of revenue, the market is expected to touch US$5.19 bn by 2020.

Request the Coronavirus Impact Analysis on this Market –  https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1181

Approval of New Drugs to Expand Market Growth

Based on drug class that includes prostacyclin and prostacyclin analogs, PDE-5 inhibitors, ERAs (endothelin receptor antagonists), and soluble guanylate cyclase (sGC) stimulators. In terms of value, ERAs segment is projected to dominate the market over the forecast tenure. On the other hand, during the forecast period prostacyclin and prostacyclin analogs segment is estimated to exceed the ERAs segment. This is because of the commercialization of novel drugs such as Uptravi (selexipag) in December 2015. Based on sGC stimulator, Adempas (riociguat) is the only certified drug used for treating PAH.

More Trending Reports by Transparency Market Research –   https://www.biospace.com/article/breast-cancer-therapeutics-market-growing-awareness-of-the-breast-cancer-further-drives-the-growth/

Comments

Post a Comment

Popular posts from this blog

Angioplasty Balloons & Stents Market Research Report | Forecast Until 2027

Complications with Existing Treatments to Drive Innovations The healthcare sector is no stranger to innovations and technological advancements. Research and development activities continue to improve the efficacy of treatments and bring forward new therapies to treat a range of diseases. Over the past couple of decades, minimally invasive procedures have gained a great amount of popularity within the healthcare sector. A similar trend can be observed within the angioplasty balloons & stents market as the adoption of minimally invasive procedures is on the rise, particularly among patients who have been diagnosed with coronary heart diseases or experienced a heart attack. Request Sample Of Report –   https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5627 At present, healthcare experts are focusing on minimizing the complications involved with the percutaneous coronary intervention (PCI) by leveraging the benefits of technology that conti...
Post a Comment
Read more

Autoimmune Disease Diagnostics Market Analysis and Forecast up to 2023

Autoimmune Disease Diagnostics Market – Snapshot When immune system attacks the body mistakenly, then the resulting condition is known as autoimmune disease. Some of the autoimmune diseases are found more commonly in certain ethnicities than others. A case in point is high prevalence of lupus amongst the Hispanic and African-American group of people rather than Caucasians. The global autoimmune disease diagnostics market is estimated to make substantial gains due to rising incidences of autoimmune diseases across the globe. Request Sample Of Report –    https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5351 Some of the autoimmune diseases such as lupus and multiple sclerosis run within families. In that case, the family members will inherit vulnerability to the autoimmune illness that runs in the family but might not necessarily be affected by it. Increased Prevalence of Autoimmune Diseases to Spell Growth of the Market Many of the auto...
Post a Comment
Read more

Analysis of COVID-19 Collagen Peptide and Gelatin Market

Collagen Peptide and Gelatin Market: Overview According to Transparency Market Research’s latest report on the global collagen peptide and gelatin market for the historical period  2017–2018  and forecast period  2019–2027 , increase in commercialization of novel collagen-based drug delivery systems and rise in social awareness about personal well-being are projected to drive the global collagen peptide and gelatin market According to the report, the global collagen peptide and gelatin market was valued at  US$ 5,976.9 Mn  in  2018  and is projected to expand at a CAGR of  8.7%  from  2019  to  2027 To know the scope of our report  Get a Sample  on Collagen Peptide and Gelatin Market Increase in social awareness about personal well-being and rigorous research and development activities in regenerative medicine and wound healing: Key Drivers Major factors driving the collagen peptide application in nutrac...
Post a Comment
Read more